南新制药(688189) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥303,227,799.34, representing a year-on-year increase of 54.09%[5] - The net profit attributable to shareholders was ¥12,532,756.73, reflecting a growth of 6.09% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 119.04% to ¥16,158,548.75[5] - Basic earnings per share increased by 5.97% to ¥0.0639[5] - Total operating revenue for Q1 2023 reached ¥303.23 million, a 54% increase from ¥196.78 million in Q1 2022[19] - Net profit for Q1 2023 was ¥14.36 million, compared to ¥6.98 million in Q1 2022, marking a 105.5% increase[20] - The company reported a total profit of ¥19.30 million for Q1 2023, up from ¥6.93 million in Q1 2022, representing a 178% increase[20] Research and Development - Research and development expenses totaled ¥34,015,766.79, marking a significant increase of 179.66%[6] - R&D expenses accounted for 11.22% of operating revenue, up by 5.04 percentage points year-on-year[6] - Research and development expenses surged to ¥34.02 million in Q1 2023, up from ¥12.16 million in Q1 2022, indicating a 179% increase[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,069,917,413.20, an increase of 5.94% from the previous year[6] - As of March 31, 2023, the total current assets amounted to RMB 1,631,204,722.21, an increase of 9.0% from RMB 1,496,172,292.33 on December 31, 2022[15] - The total liabilities increased to RMB 759,181,195.24, compared to RMB 657,420,475.62, representing a rise of 15.5%[16] - The total assets reached RMB 2,069,917,413.20, up from RMB 1,953,792,143.98, marking an increase of 5.9%[16] - The total equity attributable to shareholders increased slightly to RMB 1,326,897,296.06 from RMB 1,314,364,539.33, reflecting a growth of 0.2%[16] Cash Flow and Financial Health - Cash flow from operating activities generated a net amount of ¥2.67 million in Q1 2023, a significant recovery from a net outflow of ¥61.04 million in Q1 2022[23] - Cash and cash equivalents were reported at RMB 757,153,421.15, up from RMB 713,471,964.63, reflecting a growth of 6.1%[13] - Cash and cash equivalents at the end of Q1 2023 totaled ¥757.15 million, an increase from ¥674.86 million at the end of Q1 2022[24] Sales and Expenses - Total operating costs increased to ¥248.03 million in Q1 2023, up from ¥188.78 million in Q1 2022, representing a 31.5% rise[19] - Sales expenses rose to ¥181.42 million in Q1 2023, compared to ¥125.03 million in Q1 2022, which is a 45% increase[19] Credit and Inventory - The company incurred a credit impairment loss of ¥31.72 million in Q1 2023, compared to a loss of ¥5.71 million in Q1 2022, indicating a significant increase in credit risk[19] - Inventory levels rose to RMB 39,520,200.23 from RMB 27,014,850.74, showing a significant increase of 46.4%[15] Other Information - The company experienced a notable increase in sales of anti-influenza virus products due to a domestic flu outbreak, driving revenue growth[9] - The company reported a non-recurring loss of ¥3,625,792.02, primarily due to debt restructuring costs[9] - The company has not disclosed any new product developments or market expansion strategies in the current report[13]